What Causes PRP to Fail?

If you have had a PRP injection that did not work, you are not alone. Many patients arrive at Solutions Regenerative Medicine in the East Valley, Arizona after a previous PRP attempt left them no better. The assumption is usually that PRP itself failed. More often, what failed was a specific preparation, a specific injection, or a specific patient setup that was not optimized.

Dr. Mareshah Dunning, NMD takes a different view. PRP results vary on two axes, and an honest conversation about why PRP fails has to address both: what is in the syringe, and the patient receiving it.

Why Doesn’t PRP Work the Same for Everyone?

PRP results vary because every step of the procedure matters, and any single weak point can cause an otherwise reasonable treatment to fail. Two preparations both called PRP can differ by a factor of ten in platelet dose and a factor of one hundred in white blood cell content (Bensa et al., 2025, PMID: 39751394). Two patients with the same diagnosis can have very different inflammation status, biological age, comorbidities, and nutrient status. Both sides have to be addressed.

What Causes PRP to Fail on the Practitioner Side?

Under-dosing the platelet dose

The single most common reason PRP fails. Research points to a dose threshold of at least 4 billion platelets per injection and a cumulative course dose around 10 billion (Corsini et al., 2025, PMID: 40283544). Sub-therapeutic preparations come from both lower-end commercial kits and from manual processing techniques (such as single-spin protocols) that many clinics use to keep costs down. Both routinely deliver only 1 to 2 billion platelets per injection, well below the threshold.

The widely-cited 2021 RESTORE Trial in JAMA, often referenced as evidence that PRP does not work for knee osteoarthritis, used a preparation that delivered only about 1.6 billion platelets per injection (Bennell et al., 2021, DOI: 10.1001/jama.2021.19415). The trial demonstrated that sub-therapeutic PRP does not work, not that PRP itself does not work. A direct comparison RCT published in 2024 found that an 8 mL injection of approximately 5.65 billion platelets significantly outperformed a 4 mL conventional injection of 2.8 billion platelets across every pain and function endpoint at 6 months (Patel et al., 2024, DOI: 10.1177/23259671241227863). Dose is not a marketing variable. It is the variable.

Wrong leukocyte composition

Not all white blood cells in PRP are equal. Neutrophils release enzymes that drive catabolic inflammation, while monocytes polarize into the M2 macrophages that drive repair (Lana et al., 2019, PMID: 31700202; Chisari et al., 2021, PMID: 34863223). A preparation that contains the full white blood cell content can amplify the very inflammation the injection is trying to resolve.

Pre-activating the PRP before injection

Adding calcium chloride or thrombin before injection forces immediate growth factor release. Tissue-collagen activation in the body produces sustained release over five days, while pre-activation produces a premature burst that depletes the regenerative signal before it reaches the injury site (Harrison et al., 2011, PMID: 21398575).

Blind injection without image guidance

Without ultrasound or fluoroscopic guidance, the injection often goes near rather than into the intended target. A small tendon tear, a precise joint compartment, or a specific bursa requires real-time visualization to hit accurately. Image guidance is no longer optional for serious PRP work.

Wrong anticoagulant in the prep

Older systems use acid citrate dextrose (ACD-A), which creates an acidic preparation that burns on injection and impairs platelet function. Modern systems use sodium citrate, which maintains physiologic pH and allows normal activation and scaffold formation at the tissue site (Calciolari et al., 2024, PMID: 38487938).

Routine co-injection without clinical rationale

Some providers routinely co-inject PRP with bupivacaine or high-dose corticosteroids regardless of the patient’s clinical situation. There are specific scenarios where a low-dose steroid combined with PRP can be appropriate, such as a significantly inflamed joint where the inflammation must be addressed for PRP to work. But routine co-injection without considering the inflammatory state can blunt the regenerative response PRP was meant to deliver. A careful PRP provider tailors these decisions to the patient’s specific clinical picture rather than applying the same combination to every injection.

What Causes PRP to Fail on the Patient Side?

Advanced disease stage

A 517-patient cohort study found PRP response rates of 75% in mild knee osteoarthritis (K-L grade 2), 67% in moderate (K-L 3), and 51% in severe disease (K-L 4) (Saita et al., 2021, DOI: 10.3390/jcm10194514). In bone-on-bone arthritis, the response is more limited because the tissue substrate PRP supports is already largely gone.

Medications around the procedure

Ibuprofen, naproxen, meloxicam, and other NSAIDs block the COX-2 and prostaglandin signaling pathways that PRP delivers its repair signal into. Patients who continue NSAIDs around the time of a PRP injection often blunt the proliferative healing response PRP is designed to support. Blood thinners create separate concerns related to bleeding risk during the injection and are evaluated based on the type of procedure and established ASRA guidelines. Most experienced providers tailor NSAID and blood-thinner timing to the patient’s specific situation and procedure.

Unaddressed systemic health and biology

Untreated thyroid dysfunction, hormonal imbalances, autoimmune disease, poorly controlled diabetes, and chronic inflammation blunt the healing response. So do micronutrient deficiencies (vitamin D, ferritin, B vitamins), smoking, excessive alcohol, and poor metabolic health. The PRP may be sound, but the system receiving it is dysregulated. Dr. Dunning evaluates these as part of her Foundations of Health approach so the injection lands in an environment that can use it.

Insufficient injection series

For knee osteoarthritis specifically, the published protocol range is 1 to 3 injections depending on per-injection dose. A 2023 meta-analysis found three PRP injections significantly outperformed a single injection at 12 months when dose per injection was moderate (Tao et al., 2023, PMID: 37236291; Yurtbay et al., 2021, DOI: 10.1007/s00402-021-04230-2). A 610-patient trial of a 3-injection course at moderate dose showed approximately 75% pain reduction at 12 months that held at 67% at 24 months (Chu et al., 2022, DOI: 10.1007/s00167-022-06887-7). Stopping the series too early at a sub-therapeutic per-injection dose is one of the most common patient-side failure patterns.

How Can I Tell If a PRP Provider Is Careful?

A careful PRP provider can answer a short list of specific questions about what they actually inject and how they treat you as a whole person. Vague answers mean the preparation is probably not measured and the approach is probably not personalized.

• Image guidance: Do you use ultrasound or fluoroscopic guidance for every injection?
• Measured dose: What platelet dose, in billions, do you typically deliver per injection?
• Formulation: Is your PRP neutrophil-depleted, and why did you choose that formulation?
• Activation: Do you activate the PRP before injection, or does the tissue activate it at the injury site?
• Anticoagulant: What anticoagulant do you use? Is your preparation acidic or pH-neutral?

Whole-person evaluation: Do you check labs, medications, nutrients, and lifestyle factors before treatment?